AstraZeneca scores 13 points higher than Pfizer on SINK's sustainability index.
AstraZeneca is more sustainable according to SINK's open sustainability index, scoring 52/100 vs Pfizer's 39/100 — a difference of 13 points.
Pfizer scores 39/100 on the SINK sustainability index (Below expectations). Pfizer has disclosed detailed carbon data and joined science-based initiatives early, but execution is failing. Renewable energy adoption is stuck at 14% despite RE100 membership. Emissions trajectory lags 46% 2030 target by two-thirds. Critically, Pfizer funds trade groups actively lobbying against climate policy, undermining its public commitments.
AstraZeneca scores 52/100 on the SINK sustainability index (Making progress). AstraZeneca has cut operational emissions 77.5% since 2015 and achieved 97% renewable electricity, backed by SBTi-validated net-zero targets. But absolute Scope 3 emissions rose 18.6% from baseline, undermining the net-zero claim. Delivery gaps and rising supply chain emissions are the core weakness.
Both companies are rated on the same 10-question SINK rubric: Scope 1/2/3 carbon footprint, energy source, nature and biodiversity, resource use, water, emissions trajectory, science-based targets, transparency, and controversies. Scores are 0–100, based on public data, and fully reproducible.
See the full leaderboard — 500+ companies ranked.
View full leaderboard →